Strategic targeting Cleave is focused on VCP/p97 inhibitors with CB-5339, targeting cancer and neurodegenerative diseases. Potential sales opportunities exist with oncology and neurodegenerative disease teams seeking novel targets and mechanisms, especially in AML and solid tumors where VCP/p97 biology is compelling.

Collaborations leverage Existing and past collaborations with NCI, Jazz Pharmaceuticals, and CASI indicate a pattern of partnering to advance clinical programs. Leverage these relationships to introduce joint development or licensing discussions with nearby academic network nodes or other biopharma collaborators pursuing protein homeostasis or stress pathway targets.

Clinical momentum Lead candidate CB-5339 is in Phase 1 for AML, with broad interest from NCI for solid tumors. This suggests opportunities to align with hematology-oncology and oncology services seeking first-in-class or differentiated agents, as well as potential co-development or regional commercialization deals as trials progress.

Financing signals Significant funding and past investments (over $100M) demonstrate investor confidence and viability of the platform. Use this to frame partnership discussions around scalable development, potential co-funding, and downstream commercialization investments as programs expand.

Asset disposition Cleaves asset sale of preclinical AAA library to Eikon indicates strategic pruning and a narrowed focus on CB-5339. This focus may present a streamlined single-asset licensing or collaboration opportunity, reducing complexity for potential buyers or partners seeking a focused, actionable program.